MOTS-c Anesthesia and Perioperative Interaction: What Patients and Clinicians Need to Know

What Is MOTS-c and Why Does It Matter in the Perioperative Setting?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. It circulates endogenously, rises with exercise, and acts on skeletal muscle and adipose tissue to increase insulin sensitivity through AMPK activation. Its systemic metabolic effects are broad enough that any procedure disrupting glucose homeostasis or inflammatory balance warrants careful consideration before a patient undergoes anesthesia.

Molecular Target: AMPK and the AICAR Pathway

MOTS-c activates AMP-activated protein kinase (AMPK) by promoting accumulation of the endogenous AMPK agonist AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) [1]. AMPK is the cell's primary energy sensor. When it is activated pharmacologically during anesthesia-induced metabolic suppression, the net effect on glucose flux is unpredictable without real-time monitoring.

A 2015 Cell paper by Lee et al. (N = multiple murine cohorts plus in-vitro replication) demonstrated that systemic MOTS-c injection in mice improved insulin sensitivity and prevented high-fat-diet-induced obesity, with AMPK as the confirmed mediator [1]. Those findings establish the mechanistic basis that guides today's clinical caution.

Endogenous Levels and Surgical Stress

Plasma MOTS-c declines with age and metabolic disease [2]. Surgical stress triggers a counter-regulatory catecholamine surge that suppresses AMPK. Exogenous MOTS-c administered close to surgery could theoretically blunt that counter-regulatory response, creating a mismatch between the body's stress-glucose demand and actual glucose delivery to tissues.

How General Anesthesia Affects MOTS-c Pharmacodynamics

General anesthesia does not simply "pause" physiology. Propofol, volatile halogenated agents, and opioids each alter mitochondrial electron-transport function, hepatic glucose output, and peripheral insulin signaling, the same pathways MOTS-c targets [3].

Propofol and Mitochondrial Function

Propofol inhibits mitochondrial Complex I at clinical doses [3]. Because MOTS-c is synthesized within and signals through mitochondria, propofol's Complex I inhibition may attenuate MOTS-c's downstream AMPK activation. The practical consequence: a patient who received MOTS-c 12 hours before induction may have subtherapeutic AMPK drive during the procedure, followed by a rebound activation surge during recovery when propofol clears.

Volatile Agents and Glucose Homeostasis

Sevoflurane and desflurane suppress insulin secretion and increase hepatic glucose output, producing dose-dependent intraoperative hyperglycemia [4]. In a patient with exogenous MOTS-c on board, which enhances peripheral glucose uptake independently of insulin, the net glucose balance is difficult to predict without continuous monitoring. The American Diabetes Association recommends targeting intraoperative glucose of 140-180 mg/dL for most surgical patients [4]. That target should be maintained regardless of peptide use.

Opioid Interactions

Morphine and fentanyl activate opioid receptors on mitochondrial membranes, transiently altering mitochondrial membrane potential [5]. MOTS-c's signaling depends partly on mitochondrial membrane integrity. No human trial has tested this combination directly. The mechanistic overlap is sufficient to justify closer-than-usual glucose and hemodynamic monitoring when opioids are used in MOTS-c users.

Perioperative Cessation: How Long Before Surgery Should MOTS-c Be Stopped?

No FDA-approved label governs MOTS-c cessation timing because the peptide carries no approved indication. The guidance below is extrapolated from pharmacokinetic modeling and mechanistic reasoning.

Half-Life and Clearance Estimates

Subcutaneous peptide half-lives in the 16-amino-acid range typically span 2-6 hours, placing the 5-half-life clearance window at 10-30 hours [6]. Based on that modeling, a 24-hour cessation window before elective surgery provides reasonable metabolic clearance. Conservative programs use 48 hours when the patient is also taking insulin secretagogues or GLP-1 receptor agonists.

Practical Cessation Protocol

The HealthRX perioperative peptide framework, reviewed by our medical team, uses a three-tier cessation window based on concurrent metabolic medications:

• Tier 1 (MOTS-c alone, no other metabolic agents): Stop 24 hours before surgery.
• Tier 2 (MOTS-c plus metformin or a GLP-1 agonist): Stop 48 hours before surgery; hold metformin on the day of procedure per standard guidelines.
• Tier 3 (MOTS-c plus insulin or a sulfonylurea): Stop 48 hours before surgery; reduce sulfonylurea dose by 50% the morning of surgery; consult endocrinology.

The anesthesiologist must be informed of MOTS-c use during the pre-anesthesia assessment, ideally listed on the medication reconciliation form alongside all other peptides and supplements.

Inflammatory Pathway Effects and Surgical Wound Healing

MOTS-c suppresses NF-kB nuclear translocation and reduces TNF-alpha and IL-6 production in preclinical models [7]. Surgery triggers a deliberate inflammatory cascade required for wound healing. The question of whether anti-inflammatory peptide activity impairs surgical healing is not yet answered in human trials.

What Animal Data Suggests

A 2021 study in aged mice showed that MOTS-c administration reduced systemic inflammation markers after ischemia-reperfusion injury, a model that shares features with surgical tissue handling [7]. Wound-healing endpoints were not measured in that study, so direct extrapolation is limited.

Clinical Recommendation on Inflammation

Until prospective human data are available, patients planning major surgery with significant tissue reconstruction (orthopedic, cardiothoracic, reconstructive) should discuss a longer cessation window of 48-72 hours with their surgeon and peptide prescriber. Minor outpatient procedures carry lower theoretical risk.

Regional Anesthesia: A Lower-Risk Alternative Worth Considering

Spinal, epidural, and peripheral nerve blocks avoid propofol and volatile agents entirely, reducing the mitochondrial intersection points described above. For patients on MOTS-c who cannot discontinue the peptide before an elective procedure (for example, those enrolled in clinical trials), regional techniques merit discussion with the anesthesia team.

Regional anesthesia also blunts the surgical stress response more effectively than general anesthesia, reducing counter-regulatory catecholamine output by up to 50% in some orthopedic series [8]. That reduction in counter-regulatory hormones means glucose flux remains more predictable, which is precisely what the MOTS-c-using patient needs intraoperatively.

Can You Drink Alcohol on MOTS-c?

Alcohol and MOTS-c interact through overlapping metabolic pathways. Ethanol acutely inhibits hepatic AMPK signaling [9], which is MOTS-c's primary effector mechanism. Drinking while on MOTS-c may blunt the peptide's intended metabolic action.

Acute Ethanol and AMPK Suppression

A study published in Biochemical and Biophysical Research Communications showed that acute ethanol exposure in hepatocytes reduced AMPK phosphorylation within 30 minutes [9]. MOTS-c depends on AMPK phosphorylation for its downstream insulin-sensitizing effects. Concurrent ethanol use could render a given MOTS-c dose functionally ineffective for several hours.

Hypoglycemia Risk After Drinking

Ethanol inhibits gluconeogenesis independently of MOTS-c. If a patient takes MOTS-c to enhance glucose uptake and then consumes alcohol, which simultaneously suppresses glucose production, the combination may precipitate fasting hypoglycemia, particularly overnight [10]. Symptomatic hypoglycemia (blood glucose <70 mg/dL) can occur with no warning in this context. Patients should avoid alcohol on MOTS-c dosing days.

Drug Interactions Beyond Anesthesia

MOTS-c's AMPK activation means it interacts conceptually with any drug that also modulates AMPK, insulin signaling, or mitochondrial function.

Metformin

Metformin activates AMPK through Complex I inhibition and is the most widely prescribed insulin sensitizer globally [11]. Combining metformin with MOTS-c could produce additive AMPK activation with unpredictable glucose-lowering. No pharmacokinetic interaction study exists. Monitoring fasting glucose weekly during co-administration is prudent.

GLP-1 Receptor Agonists

Semaglutide and liraglutide reduce hepatic glucose output and increase peripheral insulin sensitivity by different mechanisms than MOTS-c, but both lower fasting glucose. In STEP-1 (N = 1,961), semaglutide 2.4 mg produced a 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [12]. Patients combining semaglutide with MOTS-c should be monitored for additive glucose-lowering effects, particularly if they are also eating less and losing weight rapidly.

Statins

Statins inhibit mitochondrial Coenzyme Q10 synthesis and reduce Complex I activity, partially overlapping with propofol's mechanism [13]. Patients on atorvastatin or rosuvastatin who also use MOTS-c may have mildly altered AMPK baseline activity. This interaction is theoretical; no clinical case series has quantified it.

Intraoperative Monitoring Priorities for MOTS-c Users

Standard ASA monitoring (ECG, pulse oximetry, capnography, non-invasive blood pressure) applies to all patients. MOTS-c users warrant two additional monitoring considerations.

Blood Glucose Monitoring

Point-of-care glucose should be checked at induction, every 60 minutes intraoperatively for procedures lasting more than 90 minutes, and at emergence. Target 140-180 mg/dL per ADA surgical guidelines [4]. Values below 100 mg/dL in a fasted MOTS-c-using patient should prompt dextrose supplementation and anesthesia team notification.

Core Temperature

MOTS-c increases brown adipose tissue thermogenesis in murine models [1]. Whether this persists at human clinical doses is unknown. Core temperature monitoring (esophageal or bladder probe) is standard for procedures longer than 60 minutes but deserves particular attention in MOTS-c users to detect unexpected thermogenic fluctuations under neuraxial or general anesthesia.

Postoperative Recovery Considerations

The postoperative period reintroduces normal eating and medication schedules, which can produce abrupt metabolic shifts in patients who are also restarting MOTS-c.

Restarting MOTS-c After Surgery

Resume MOTS-c only after the patient is tolerating oral or enteral nutrition and blood glucose has been stable for at least 12 hours without IV dextrose supplementation. For major surgeries with prolonged NPO periods, restart should be confirmed with the prescribing clinician rather than defaulted to the pre-surgical schedule.

Post-Anesthesia Cognitive Effects and AMPK

A small but growing body of literature links perioperative cognitive dysfunction (POCD) to mitochondrial stress, particularly in older adults [14]. MOTS-c's capacity to reduce mitochondrial oxidative stress in preclinical models raises the hypothesis that pre-conditioning with MOTS-c could theoretically mitigate POCD. This remains speculative. A 2022 review in Ageing Research Reviews noted that MOTS-c "extends lifespan and healthspan across multiple organisms" via mitochondrial stress signaling but did not test surgical outcomes [15]. That mechanistic connection does not constitute clinical evidence; prospective trials are needed before MOTS-c is used with any neuroprotective intent around surgery.

What Clinicians Should Document Before Surgery

Anesthesiologists and surgeons should obtain the following before proceeding on any patient disclosing MOTS-c use:

• Dose and frequency of MOTS-c (typically 5-10 mg subcutaneous, 2-5 times weekly in research protocols)
• Last dose relative to planned procedure time
• Concurrent metabolic medications (metformin, GLP-1 agonists, insulin, sulfonylureas)
• Pre-operative fasting glucose
• Any history of hypoglycemic episodes on MOTS-c

This information should be documented in the anesthesia pre-assessment note and communicated to the PACU team at handoff.

Regulatory Status and Informed Consent

MOTS-c has no FDA-approved indication as of 2025 [16]. It is classified as a research chemical in the United States and is not available through compounding pharmacies under the same regulatory pathway as, for example, FDA-approved peptides. Patients using MOTS-c obtained through research channels must be counseled that perioperative guidance is based on mechanistic extrapolation, not controlled clinical trial data. Informed consent for elective procedures should document that the patient disclosed off-label peptide use and understands the current evidence limitations.

The FDA has previously issued guidance on the distinction between compounded drug products and research chemicals, noting that unapproved substances lack the safety and efficacy data required for labeling [16]. That regulatory gap means the entire perioperative protocol described in this article is based on first-principles pharmacology, not product-specific clinical trials.